AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06299813
Drug: Bentelan
RxNorm normalized name: Betnelan
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The experimental treatment group will be administered betamethasone 0.1 mg per kg.
Trial: NCT05200052
Drug: Colchicine 0.5 mg Oral Tablet
RxNorm normalized name: colchicine 0.5 mg oral tablet
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine loading dose 1 mg and maintenance dose 0.5 mg for 6 months in addition to standard anti ischemic treatment.
Trial: NCT05092880
Drug: Standard of care first-line systemic therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capecitabine plus anti-VEGF antibody
Trial: NCT05466734
Drug: Cilostazol Tablet 100 mg
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two oral doses (total daily dose of 200 mg)
Trial: NCT04747522
Drug: SARS-CoV-2 vaccine
RxNorm normalized name: SARS-CoV-2 vaccine
DrugBank: BNT162b1 SARS-CoV-2 Vaccine (DB15695)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 vaccines currently on market, i.e. Pfizer/BioNTech and Moderna
Trial: NCT05574439
Drug: Semaglutide 3 mg/ml
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.
Trial: NCT05574439
Drug: Placebo (Semaglutide 3 mg/ml)
RxNorm normalized name: semaglutide 3 MG
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.
Trial: NCT05560607
Drug: AZD7503 Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part A: Participants will be screened for histologic evidence of NAFLD or NASH and all eligibility criteria in part A prior to enrollment in part B.~Part B: Participants consented to part B will be administered the study drug over the course of 31 days. At the end of the study a liver biopsy will be collected to measure for endpoints.
Trial: NCT05814731
Drug: MA-BUCY2
RxNorm normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone liposome 20mg/m2，ivgtt，d-11 ；Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
Trial: NCT05814731
Drug: BUCY2
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
Trial: NCT06530797
Drug: First-line Adebrelimab regiment for advanced stage ES-SCLC
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line Adebrelimab in any regiment for advanced stage ES-SCLC
Trial: NCT06530797
Drug: Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLC
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line and beyond Adebrelimab in any regiment for advanced stage ES-SCLC
Trial: NCT05027204
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel for Injection (Albumin-bound), Q3W, i.v. 60 min
Trial: NCT05027204
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab, Q3W, i.v. 30 min
Trial: NCT00028171
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04996979
Drug: Ropivacaine 0.5% Injectable Solution
RxNorm normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local anaesthetic solution composed of ropivacaine 0.5%(intervention group)
Trial: NCT06384833
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NAC (effervescent) 600mg 1 tab PO OD for 45 days
Trial: NCT04599075
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Insulin Infusion
Trial: NCT04599075
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous Subcutaneous Insulin Infusion (Pump)
Trial: NCT04665986
Drug: Navelbine
RxNorm normalized name: Navelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Navelbine 25mg/m2 on day 1 and 8, every 3 weeks
Trial: NCT04665986
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 90mg/m2 on day 1, every 3 weeks
Trial: NCT06581679
Drug: Triptorelin
RxNorm normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRHa will be given as a subcutaneous injection of triptorelin in a dose of 3.75 mg monthly for three months.
Trial: NCT06531278
Drug: Irinotecan liposome
RxNorm normalized name: Irinotecan liposome
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Patients are planned to receive irinotecan liposomal (60 mg/m2; d1) of every cycle.~* 27 days a cycle
Trial: NCT06531278
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Patients are planned to receive Adebrelimab (20 mg/kg; d1) of every cycle.~* 27 days a cycle
Trial: NCT06531278
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Patients are planned to receive Oxaliplatin (85 mg/m2; d1) of every cycle.~* 27 days a cycle
Trial: NCT06531278
Drug: Calcium folinate
RxNorm normalized name: Calcium folinate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Patients are planned to receive Calcium folinate (400mg/m2; d1) of every cycle.~* 27 days a cycle
Trial: NCT05697614
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valproic acid is used for general epilepsy type, used in experimental group
Trial: NCT05697614
Drug: Carbamazepin
RxNorm normalized name: Carbamazepin
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: carbamazepine is used for focal type epilepsy, used in experimental group
Trial: NCT05697614
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lamotrigine is used for general epilepsy type, used in control group
Trial: NCT05697614
Drug: Clobazam
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clobazam is used for both general or focal epilepsy in case if lamotrigine or oxcarbazepine is not possible to be administered and is used particularly in myoclonic jerk , used in control group
Trial: NCT05017246
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: -Epidural bupivacaine 0.1% 2-6ml/hr based on MAP within 10% of patient's baseline MAP
Trial: NCT05017246
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: -Preservative-free intrathecal morphine (duramorph) 150mcg injection (0.15ml or a 0.5mg/0.5ml prepared solution)
Trial: NCT05017246
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: -Lidocaine infusion 1 mg/kg ideal body weight (IBW)
Trial: NCT00037583
Drug: Gemtuzumab Ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04459234
Drug: Ketamine use in CLCC sites (indication and administration protocol)
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Collection of information concerning Ketamine use by French CLCCs pain teams (first prescription):~1. Indications : analgesic treatment of cancer chronic pain, analgesic treatment for a post-cancer treatment chronic pain, help for withdrawal from opioid treatment prescribed for a chronic cancer pain~2. Administration protocol: route, posology, duration, administration sequence, premedication~3. Antalgic efficacy~4. Tolerance profile~5. Quality of life, anxiety and depression evaluations
Trial: NCT06328049
Drug: Trilaciclib Injection
RxNorm normalized name: trilaciclib Injection
DrugBank: Trilaciclib (DB15442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with lung adenocarcinoma were given Trilaciclib combined with pemetrexed and carboplatin, Q3W; For patients with lung squamous cell carcinoma,Trilaciclib combined with paclitaxel/albumin-bound paclitaxel and carboplatin, Q3W. From cycle 2 onwards, patients chose whether to use trasylol with chemotherapy.
Trial: NCT04873596
Drug: Nebulized dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: parturient will receive nebulized 3ug/kg dexmedetomidine.
Trial: NCT04873596
Drug: Nebulized midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: parturient will receive nebulized 0.2 mg/kg midazolam.
Trial: NCT04944173
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive durvalumab 1500mg IV every four weeks for four cycles, undergo assessment for residual disease, then a subset of subjects will receive an additional eight cycles of durvalumab.
Trial: NCT01101412
Drug: Edetate Calcium Disodium
RxNorm normalized name: Edetate Calcium Disodium
DrugBank: Edetate calcium disodium anhydrous (DB14598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given through CVC or PVC.
Trial: NCT01101412
Drug: Trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given through CVC or PVC
Trial: NCT00002425
Drug: Saquinavir
RxNorm normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004981
Drug: Abacavir sulfate, Lamivudine and Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004981
Drug: Lamivudine/Zidovudine
RxNorm normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004981
Drug: Abacavir sulfate
RxNorm normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT06376058
Drug: Chloroprocaine 1% Injectable Solution
RxNorm normalized name: chloroprocaine 1% injectable solution
DrugBank: Procaine (DB00721)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: • in parturients allocated to the chloroprocaine group, a fixed dose of chloroprocaine 1% will be administered intrathecally
Trial: NCT06376058
Drug: Ropivacaine 0.75% Injectable Solution
RxNorm normalized name: ROPivacaine 0.75% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: • in parturients allocated to the ropivacaine group, a fixed dose of ropivacaine 0.75% will be administered intrathecally
Trial: NCT05442801
Drug: Cyclopentolate
RxNorm normalized name: Cyclopentolate
DrugBank: Cyclopentolate (DB00979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Well known eye drop used for cycloplegic refraction among children.
Trial: NCT05442801
Drug: Tropicamide
RxNorm normalized name: Tropicamide
DrugBank: Tropicamide (DB00809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Well known eye drop used for cycloplegic refraction among children.
Trial: NCT05623501
Drug: Dihydromyricetin
RxNorm normalized name: Dihydromyricetin
DrugBank: Dihydromyricetin (DB15645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalation and lysine preparation
Trial: NCT00002346
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00594373
Drug: Tenofovir gel
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 gm/100 ml of 1% tenofovir gel vaginally daily
Trial: NCT00594373
Drug: Tenofovir gel placebo
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 gm/100 ml of placebo gel vaginally daily
Trial: NCT05680584
Drug: Hydroxyzine Pill
RxNorm normalized name: hydroxyzine Pill
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/ kg hydroxyzine in 10 ml apple juice 1 hour before induction of anesthesia
Trial: NCT06331169
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.
Trial: NCT06331169
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.
Trial: NCT04801511
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose Intravenous Vitamin C will be delivered on the day of radiotherapy, in order to reduce the acute toxicity of chemoradiotherapy.
Trial: NCT06054035
Drug: Dapagliflozin (Forxiga®)
RxNorm normalized name: dapagliflozin Oral Tablet [Farxiga]
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10 mg once daily for 2 years. Route of administration: oral.
Trial: NCT06551207
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib:5mg ,qd,po, d1-d14, q3w
Trial: NCT06551207
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab:10mg/kg, ivgtt, d1, q3w
Trial: NCT05259527
Drug: Ergocalciferol Capsules
RxNorm normalized name: Ergocalciferol Capsules
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin D2 50,000IU by mouth once weekly for 8 weeks then once per month thereafter.
Trial: NCT04902937
Drug: neoadjuvant and adjuvant chemotherapy
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guideline-based therapy of primary non-metastatic early breast carcinoma
Trial: NCT05305066
Drug: Anti-IL6
RxNorm normalized name: IL6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IL6 receptor monoclonal antibodies - tocilizumab (if weight \<100 kg: 162 mg SC every other week, followed by an increase to weekly based on clinical response; if weight ≥100 kg: 162 mg SC weekly) or sarilumab (200 mg SC once every 2 weeks)
Trial: NCT05806996
Drug: Magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion, load 50 mg/Kg with infusion of 15 mg/Kg/hour
Trial: NCT06045013
Drug: 5% dextrose injection
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ultrasound-guided injection of 4 ml 5% dextrose in carpal tunnel via ulnar approach.
Trial: NCT05924321
Drug: Carbetocin
RxNorm normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single infusion of Carbetocin
Trial: NCT05924321
Drug: Placebo and Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single IV infusion of matching placebo in combination with Single Oral dose of Moxifloxacin
Trial: NCT05423132
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients will receive 15 ml of Ropivacaine 0.375 % on each side.
Trial: NCT05423132
Drug: Physiological serum injection
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive 15 ml of physiological serum (NaCl 0.9 %) on each side.
Trial: NCT06511765
Drug: Ropivacaine and dexamethasone injection solution
RxNorm normalized name: ropivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of Ropivacaine and dexamethasone
Trial: NCT06511765
Drug: Sodium Chloride 0.9% Injection Solution
RxNorm normalized name: Sodium Chloride 0.9% Injection Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of sodium chloride 0.9%
Trial: NCT06392529
Drug: Voriconazole Powder
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The drug will be topically applied for vagina of patients suffering from vaginal Candidasis albican
Trial: NCT04552795
Drug: 3TC
RxNorm normalized name: 3TC
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 subjects will be administered 3TC, 300mg once daily, via an oral tablet for 24 weeks.
Trial: NCT06531837
Drug: Esketamine(Continuous infusion)
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Continuous intravenous infusion of esketamine at a dose of 0.2 mg/(kg · h). Collect resting-state EEG data and NRS scores 40 minutes after administration.
Trial: NCT04759196
Drug: Topamax
RxNorm normalized name: Topamax
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TPM : 50 mg BID, with increased of 50 mg by week until efficacy, to a maximum of 100 mg BID.
Trial: NCT04759196
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: LEV : 500 mg BID, with increase of 1000 mg die divided in two doses each week until efficacy, to a maximum of 1500 mg BID.
Trial: NCT04671589
Drug: Meropenem Injection
RxNorm normalized name: meropenem Injection
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration Intravenous meropenem 1gram every 8 hours together with standard care;~.
Trial: NCT00380835
Drug: Amrubicin
RxNorm normalized name: amrubicin
DrugBank: Amrubicin (DB06263)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04859452
Drug: Metformin hydrochloride tablets
RxNorm normalized name: Metformin Hydrochloride Tablets
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug: Metformin hydrochloride, tablet, oral
Trial: NCT04859452
Drug: Glibenclamide tablets
RxNorm normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Glibenclamide, tablet, oral
Trial: NCT04859452
Drug: Valsartan Capsules
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Valsartan, capsule, oral
Trial: NCT05856851
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm/group descriptions.
Trial: NCT05549505
Drug: ARV-471
RxNorm normalized name: Arv-110 (protac)
DrugBank: Bavdegalutamide (DB19032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT05549505
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg tablet
Trial: NCT05310071
Drug: Aducanumab
RxNorm normalized name: Aducanumab
DrugBank: Aducanumab (DB12274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT00399048
Drug: OROS hydromorphone HCL ; OxyContin
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04952350
Drug: Atorvastatin 40 Mg Oral Tablet
RxNorm normalized name: atorvastatin 40 mg oral tablet
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive Atorvastatin 40 mg orally within 24 hrs after hospital admission after evaluation of the clinical and laboratory inclusion criteria.
Trial: NCT00000714
Drug: Trimetrexate glucuronate
RxNorm normalized name: Trimetrexate Glucuronate
DrugBank: Trimetrexate (DB01157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06513481
Drug: Nardraparin calcium injection
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
Trial: NCT05883124
Drug: Rivastigmine twice-weekly 9,5 mg/24 h
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
Trial: NCT05317312
Drug: MR-107A-02
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MR-107A-02 oral tablet